Shukra Pharmaceuticals Ltd
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
- Market Cap ₹ 1,315 Cr.
- Current Price ₹ 30.0
- High / Low ₹ 30.0 / 5.75
- Stock P/E 130
- Book Value ₹ 1.44
- Dividend Yield 0.03 %
- ROCE 21.8 %
- ROE 15.9 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 244% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.6%
- Debtor days have improved from 135 to 98.2 days.
Cons
- Stock is trading at 20.9 times its book value
- Earnings include an other income of Rs.4.61 Cr.
- Working capital days have increased from 201 days to 404 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 | 3 | 5 | 5 | 5 | 6 | 12 | 11 | 20 | 59 | 75 | 33 | 35 | |
5 | 3 | 4 | 4 | 4 | 4 | 10 | 10 | 18 | 53 | 55 | 20 | 22 | |
Operating Profit | -0 | -0 | 1 | 1 | 2 | 2 | 2 | 1 | 3 | 5 | 19 | 13 | 13 |
OPM % | -2% | -10% | 24% | 28% | 30% | 29% | 13% | 13% | 14% | 9% | 26% | 39% | 38% |
0 | 1 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 5 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Depreciation | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 |
Profit before tax | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 | 20 | 13 | 14 |
Tax % | 9% | 52% | 66% | 52% | 45% | 37% | 82% | -90% | 26% | 1% | 7% | 28% | |
-1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 | 19 | 10 | 10 | |
EPS in Rs | -0.02 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.10 | 0.42 | 0.22 | 0.22 |
Dividend Payout % | 0% | 0% | 0% | 16% | 15% | 17% | 0% | 0% | 10% | 4% | 6% | 5% |
Compounded Sales Growth | |
---|---|
10 Years: | 29% |
5 Years: | 22% |
3 Years: | 17% |
TTM: | -40% |
Compounded Profit Growth | |
---|---|
10 Years: | 53% |
5 Years: | 244% |
3 Years: | 134% |
TTM: | -46% |
Stock Price CAGR | |
---|---|
10 Years: | 61% |
5 Years: | 159% |
3 Years: | 205% |
1 Year: | 377% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 22% |
3 Years: | 27% |
Last Year: | 16% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 11 | 44 |
Reserves | 12 | 12 | 13 | 13 | 13 | 14 | 14 | 14 | 15 | 21 | 47 | 19 |
0 | 1 | 0 | 0 | 4 | 6 | 8 | 10 | 3 | 5 | 3 | 4 | |
4 | 3 | 3 | 4 | 6 | 7 | 10 | 10 | 15 | 45 | 17 | 20 | |
Total Liabilities | 18 | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 |
10 | 10 | 10 | 10 | 14 | 16 | 17 | 18 | 18 | 20 | 20 | 19 | |
CWIP | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
7 | 7 | 6 | 7 | 8 | 11 | 14 | 16 | 16 | 53 | 56 | 65 | |
Total Assets | 18 | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-3 | -2 | 3 | -0 | 1 | 0 | 1 | 1 | 8 | 3 | -5 | 8 | |
-10 | 1 | -0 | -1 | -5 | -2 | -3 | -2 | -2 | -4 | -1 | -1 | |
-18 | 1 | -1 | 0 | 3 | 2 | 2 | 2 | -7 | 5 | 12 | -5 | |
Net Cash Flow | -31 | 0 | 1 | -1 | -0 | 0 | -0 | 0 | -0 | 4 | 6 | 2 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 45 | 73 | 71 | 175 | 200 | 345 | 245 | 318 | 132 | 187 | 120 | 98 |
Inventory Days | 134 | 554 | 92 | 112 | 53 | 100 | 169 | 221 | 139 | 25 | 19 | 447 |
Days Payable | 209 | 291 | 108 | 400 | 734 | 1,161 | 786 | 702 | 303 | 271 | 59 | 414 |
Cash Conversion Cycle | -30 | 335 | 54 | -112 | -480 | -717 | -372 | -163 | -32 | -58 | 80 | 131 |
Working Capital Days | 368 | 758 | 258 | 344 | 379 | 440 | 226 | 278 | 57 | 41 | 157 | 404 |
ROCE % | -6% | -1% | 6% | 7% | 6% | 4% | 0% | 1% | 6% | 19% | 44% | 22% |
Documents
Announcements
- Intimation Of Record Date For Final Dividend For Financial Year 2024-2025. 12 Sep
- Intimation Of Book Closure And Record Date Pursuant To Regulation 42 Of SEBI Listing Regulations For Annual General Meeting Of The Company. 12 Sep
-
Corrigendum To The Notice Of 32ND Annual General Meeting And Annual Report (2024-25) Of The Company
12 Sep - Record date for dividend corrected to Thursday, September 18, 2025 for FY2024-25.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
10 Sep - Newspaper Advertisement Of Notice Of 32nd Annual General Meeting[AGM]
-
Announcement Under Regulation 30 Of SEBI (LODR)- Strategic PAN India Distribution Tie-Up
10 Sep - Authorized by Wockhardt on Sep 9, 2025 for PAN-India ESIC/Defence distribution till Mar 2026 of EMROK and MIQNAF.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
SPL is a is WHO-GMP certified integrated manufacturer of formulations like tablet, capsules and small volume parenteral. It has assisted in the development and manufacture
of a variety of drugs and dosage forms and potency variations for many pharmaceutical companies